US Approves Lenacapavir, Nigeria Among Beneficiaries of Anti-HIV Vaccine

The first generic version of lenacapavir, a twice-yearly injection used to prevent HIV infection, has been given tentative approval by the U.S. Food and Drug Administration (FDA), in a major development for global HIV prevention. adsbygoogle || []).push({});

The generic drug which has been developed by India’s Dr Reddy’s Laboratories, and is expected to cost about $40 per person annually, will be made available across 120 low- and middle-income countries, including Nigeria.

The injection has demonstrated near-total effectiveness in clinical trials, offering an alternative to daily HIV prevention pills. The approval is expected to accelerate access to affordable prevention options, although local regulatory processes, funding and distribution remain key to its rollout.